GU Cancers Symposium 2013 - Sipuleucel-T delayed time to first use of opioid analgesics in patients with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer in the IMPACT trial, by Eric J. Small, MD, et al. - Poster

ORLANDO, FL, USA (UroToday.com) - Sipuleucel-T is an autologous cellular immunotherapy designed to stimulate an immune response against prostate cancer. Sipuleucel-T has been demonstrated to improve overallsurvival in three Phase III trials (including the pivotal IMPACT study) in patients with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC)....Click here to enlarge and view the poster.

IMPACT TFOA Sip-T small thumb
                                (Click thumbnail to enlarge poster)

 

Presented by Eric J. Small,1 Celestia S Higano,2 Philip W Kantoff,3 James B Whitmore,4 Mark W Frohlich,4 and Daniel P Petrylak5 at the 2013 Genitourinary Cancers Symposium - February 14 - 16, 2013 - Rosen Shingle Creek - Orlando, Florida USA

1Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, CA, USA; 2Departments of Oncology and Urology, School of Medicine, University of Washington, Seattle, WA, USA; 3Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; 4Dendreon Corporation, Seattle, WA, USA; 5Department of Medical Oncology, Smilow Cancer Hospital at Yale, New Haven, CT, USA



gucancerssympalt



View Full 2013 GU Cancers Symposium Coverage



 

 

 

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe